Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws related to the efficacy claims of its drug reproxalap for dry eye disease [1][3]. Group 1: Company Developments - Throughout 2024 and 2025, Aldeyra made optimistic forward-looking statements regarding the development and regulatory prospects of reproxalap, emphasizing its importance in the company's pipeline and commercial potential [2]. - The FDA issued a Complete Response Letter on March 17, 2026, indicating that reproxalap did not demonstrate sufficient efficacy, contradicting the company's previous positive public statements about the drug's clinical data [3]. Group 2: Legal Investigation - Levi & Korsinsky is investigating whether Aldeyra failed to disclose material information regarding efficacy risks that could have significantly altered the forward-looking statements made to shareholders [3].

Core Viewpoint - The PayPal class action lawsuit alleges that the company and certain executives misled investors regarding the company's revenue outlook and growth potential during the specified Class Period, leading to significant financial losses for shareholders [3][4]. Group 1: Class Action Details - The lawsuit is titled Darcy v. PayPal Holdings, Inc., and it allows investors who purchased PayPal common stock between February 25, 2025, and February 2, 2026, to seek appointment as lead plaintiff by April 20, 2026 [1]. - The lawsuit claims that PayPal's management created a false impression of the company's financial health and growth prospects, particularly regarding its Branded Checkout offerings [3]. Group 2: Financial Performance and Impact - On February 3, 2026, PayPal reported disappointing earnings for Q4 and the full fiscal year 2025, which included a decline in Branded Checkout performance and the withdrawal of previously set 2027 financial targets [4]. - Following the announcement of these results and the transition of CEO James Alexander Chriss, PayPal's stock price reportedly fell by more than 20% [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired PayPal stock during the Class Period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all investors [5]. - The lead plaintiff has the authority to select a law firm for litigation, but participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering a total of $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [6].

Core Viewpoint - Ademi LLP is investigating potential securities fraud claims against Microvast Holdings, Inc. due to possible inaccuracies in the company's financial statements, business operations, and future prospects [1]. Group 1: Investigation Focus - The investigation is centered on whether Microvast accurately disclosed regulatory changes in the Korean market [2]. - It also examines delays in the ramp-up of customer platforms that may not have been properly communicated [2]. Group 2: Legal Context - Ademi LLP specializes in securities fraud and shareholder litigation, indicating a focus on protecting shareholder interests [2]. - The firm is inviting shareholders to join the investigation without any cost or obligation [2].

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Alight, Inc. (NYSE: ALIT) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Alight securities between November 12, 2024 and February 18, 2026, both dates i ...

Core Viewpoint - A class action lawsuit has been filed against Camping World Holdings, Inc. for allegedly misleading investors regarding its inventory management and consumer demand capabilities during the specified class period from April 29, 2025, to February 24, 2026 [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired Camping World shares during the class period [1][2]. - Investors have until May 11, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint alleges that Camping World misrepresented its ability to manage inventory and consumer demand effectively through data analytics [3]. - It is claimed that the company overstated retail demand and its inventory management capabilities while failing to disclose the need for strict corrective measures that would adversely affect gross profit and margins [3]. Group 3: Financial Performance and Market Reaction - On October 28, 2025, Camping World reported a decline in new vehicle revenue, lower average selling prices, and decreased gross margins, resulting in a share price drop of $4.17, or 24.8%, to close at $12.65 [4]. - On February 24, 2026, the company announced the implementation of strict inventory management objectives, leading to a net loss of $109.1 million for Q4 2025 and the suspension of its quarterly dividend, causing shares to fall by $1.79, or 16.5%, to close at $9.06 [5].

Core Viewpoint - A securities class action has been initiated against Soleno Therapeutics, Inc. due to alleged misrepresentations regarding the integrity of clinical trials and drug safety, particularly concerning its product DCCR (VYKAT XR) [1][3][6] Group 1: Lawsuit Details - The class action seeks to recover damages for investors who purchased Soleno securities between March 26, 2025, and November 4, 2025 [2] - Investors have until May 5, 2026, to seek lead plaintiff status in the lawsuit [3] Group 2: Product and Clinical Trials - DCCR is a diazoxide choline extended-release tablet aimed at treating hyperphagia in patients with Prader-Willi syndrome, with its FDA approval reliant on a pivotal Phase 3 clinical trial [3] - The pivotal study, a randomized withdrawal period of Study C602, is critical as it underpins the drug's approval and commercial viability [3] Group 3: Allegations of Clinical Trial Issues - The lawsuit claims that Soleno's Phase 3 program had systematic issues that were either known or recklessly ignored by the defendants [4] - Allegations include the downplaying of serious side effects such as fluid retention, which could lead to pulmonary edema and heart failure [4] - The complaint highlights a linear increase in prediabetes and diabetes markers over three years of treatment, raising concerns about the drug's safety profile [5] Group 4: Criticism from Medical Community - Endocrinologists and investigators have expressed skepticism regarding the drug's safety, with some indicating they would not prescribe it due to trial conduct issues [5] - The original 13-week Phase 3 trial did not meet its primary endpoint for hyperphagia improvement, and the pivotal study had a small sample size of only 77 participants, heavily skewed towards one clinical site [5] Group 5: Management's Communication - Despite the concerns raised, Soleno's management reportedly assured investors of the drug's "well-established safety profile" and claimed that "no new safety signals" had emerged post-marketing [6]

Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for allegedly misleading investors about its relationship with Microsoft, leading to significant stock losses when the truth was revealed [1][3]. Company Overview - Richtech Robotics Inc. is headquartered in Las Vegas, Nevada, and specializes in the design and manufacture of AI-driven service robots, providing automation solutions for industries such as hospitality, healthcare, and manufacturing [2]. Lawsuit Details - The lawsuit claims that during the class period from January 27, 2026, to January 29, 2026, Richtech misrepresented its relationship with Microsoft as a "hands-on collaboration" and "joint engineering effort," when it was actually a standard customer relationship [3]. - Following the revelation of the true nature of the relationship on January 27, 2026, Richtech's shares experienced a substantial decline, resulting in heavy losses for investors [3]. Investor Information - Investors who purchased Richtech securities during the class period have until April 3, 2026, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - ODDITY Tech Ltd. is facing a securities fraud lawsuit due to alleged misleading statements regarding its digital advertising model, which has resulted in significant financial losses for institutional investors [2][4]. Financial Impact - ODD shares experienced a decline of $14.28 per share, representing a 49.21% drop following the company's disclosure on February 25, 2026, about an algorithm change by its largest advertising partner that led to increased customer acquisition costs [2]. - Management projected a revenue decline of approximately 30% year-over-year for Q1 2026 [2]. Legal Proceedings - A securities class action has been filed in the U.S. District Court for the Southern District of New York, alleging violations of the Securities Exchange Act of 1934 by ODDITY and certain officers [2][3]. - The lawsuit claims that the company concealed critical disruptions in its advertising model while continuing to issue optimistic financial guidance [3][4]. Institutional Investor Role - Institutional investors are encouraged to assess their potential role as lead plaintiffs in the class action, as their participation can enhance the litigation process and recovery efforts [4][5]. - The deadline for applying for lead plaintiff appointment is set for May 11, 2026 [6]. Financial Obligations - Fiduciaries overseeing portfolios with ODD securities during the class period may have a duty to evaluate participation in the lawsuit to avoid scrutiny from beneficiaries and oversight bodies [5].

Core Viewpoint - Nektar Therapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding patient enrollment compliance in its pivotal REZOLVE-AA clinical trial, which has resulted in significant investor losses [1][4][6]. Group 1: Lawsuit Details - The class action seeks to recover damages for investors who purchased Nektar securities between February 26, 2025, and December 15, 2025 [2]. - Nektar's shares fell by $4.14, or 7.77%, closing at $49.16 on December 16, 2025, after the company disclosed that four patients with major study eligibility violations were included in the REZOLVE-AA trial [3]. - Investors have until May 5, 2026, to seek lead plaintiff status in the lawsuit [3]. Group 2: Clinical Trial Enrollment Issues - The REZOLVE-AA trial required strict patient screening criteria, including a SALT score between 50 and 100, stable disease for at least six months, and completion of an eight-week washout period from prior medications [3]. - The lawsuit claims that Nektar failed to enforce these standards, resulting in the randomization of four ineligible patients, which represented over 4% of the total 94 patients randomized in the study [4][5]. - The trial's primary endpoint narrowly missed statistical significance when including the ineligible patients, with p-values of 0.186 and 0.121 for the two dosing arms [5]. Group 3: Management's Misrepresentation - Nektar management allegedly misled investors by repeatedly assuring them that enrollment followed applicable instructions and protocol standards, despite the enrollment failures [5][6]. - The complaint highlights a significant gap between Nektar's representations about its enrollment procedures and the actual occurrences at its trial sites [4][6]. - The integrity of Nektar's clinical enrollment process is called into question, as shareholders were not provided with accurate information regarding the trial's compliance with protocols [7].

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. on behalf of investors who acquired its securities during the specified Class Period, alleging misrepresentation of the company's financial condition [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who purchased Beyond Meat securities from February 27, 2025, to November 11, 2025 [1][2]. - Investors have until March 24, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations - The complaint alleges that Beyond Meat misrepresented its financial condition by failing to disclose that the book value of certain long-lived assets exceeded their fair value, leading to a likely material non-cash impairment charge [3]. - Following disclosures starting October 24, 2025, Beyond Meat revealed $77.4 million in impairment charges related to long-lived assets, which caused a decline in the company's stock price and significant harm to investors [3].